Softgel Supplement Contract Manufacturer Selection: Compatibility, Cross-Linking, BSE/TSE, TOTOX and the Audit Pack
Softgels are the highest-margin liquid-fill dose form in dietary supplements — and the most chemistry-sensitive.
In Short
- A softgel is a fill (oil, suspension, semi-solid, paste) inside a shell (gelatin or HPMC/starch with plasticiser, typically glycerol or sorbitol).
- Gelatin cross-linking is the chemistry behind the most common softgel stability failure: the gelatin amine groups react with aldehydes (from the fill, from packaging…
- Bovine and porcine gelatin is regulated under EMA's Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathies via Human and…
A poorly chosen shell cross-links over shelf life and the dissolution fails 12 months in; a bovine gelatin source without proper BSE/TSE documentation closes the door to EU and UK markets; a fish-oil fill with a TOTOX above 26 reaches retailer rejection before the brand ships its second PO. This guide is the buyer's selection framework for US and UK softgel CMOs: the fill-shell compatibility decision, the cross-linking control programme, the BSE/TSE documentation pack, the fish-oil oxidation discipline (PV/AV/TOTOX), and the 21 CFR 111 + NSF 173 / USP <2750> audit overlay.
Fill-shell compatibility — the decision that prevents 12-month stability failure
A softgel is a fill (oil, suspension, semi-solid, paste) inside a shell (gelatin or HPMC/starch with plasticiser, typically glycerol or sorbitol). Compatibility is the chemistry between fill and shell over time: an aldehyde, ketone or reducing sugar in the fill cross-links gelatin (the shell hardens, dissolution slows, the product fails USP <2040> at 6–12 months); a high-water fill migrates plasticiser into the shell (the shell softens and the softgel sticks); a strongly polar fill extracts the plasticiser (the shell embrittles and cracks).
More on fill-shell compatibility — the decision that prevents 12-month stability failure
The CMO must run a pre-formulation compatibility study (binary stress at 40°C/75% RH, open and closed) before scale-up and present the data — not assume.
Gelatin cross-linking — the dissolution failure most softgel brands hit eventually
Gelatin cross-linking is the chemistry behind the most common softgel stability failure: the gelatin amine groups react with aldehydes (from the fill, from packaging headspace) or under heat/humidity stress and form a 'pellicle' — an insoluble film at the shell-fill interface that delays disintegration. USP <2040> requires that a softgel still disintegrate within 30 min (immediate-release) or 60 min (enteric) at end of shelf life; cross-linking pushes the time past the limit.
More on gelatin cross-linking — the dissolution failure most softgel brands hit eventually
Control levers: (a) HPMC/starch shells eliminate the chemistry entirely (and serve vegan markets), (b) pancreatin/pepsin addition to the dissolution medium per USP allowance can rescue test results, (c) tighter aldehyde spec on the fill ingredients, (d) low-aldehyde gelatin and tighter glycerol grade. Demand the CMO's cross-linking risk assessment and the dissolution method choice.
BSE/TSE — the documentation gate to EU/UK markets
Bovine and porcine gelatin is regulated under EMA's Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathies via Human and Veterinary Medicinal Products (EMA/410/01 rev.3) and ICH Q5A(R2). Every batch of bovine gelatin entering the EU/UK supply chain needs a TSE Certificate of Suitability (CEP/COS) from EDQM tracing the country of origin, the tissue type (skin and bone hide vs bone), the alkaline-acid processing, and the herd traceability.
More on bSE/TSE — the documentation gate to EU/UK markets
Without the CEP/COS the gelatin cannot be used in EU/UK softgels — irrespective of US legality. Demand the supplier CEP/COS upfront and the CMO's protocol for verifying it lot by lot.
Fish-oil & omega-3 — PV, AV, TOTOX and the GOED voluntary monograph
Fish-oil and omega-3 softgels are the highest-volume softgel category and the most oxidation-prone. The GOED Voluntary Monograph (current revision) sets industry-accepted limits: Peroxide Value (PV) ≤5 meq/kg, Anisidine Value (AV) ≤20, TOTOX (2·PV + AV) ≤26, plus secondary oxidation markers and contaminant limits (PCBs, dioxins, heavy metals).
More on fish-oil & omega-3 — PV, AV, TOTOX and the GOED voluntary monograph
Retailer audit (NSF, IFOS, Friend of the Sea) will reject a lot above TOTOX 26 even when GMP is in order. The CMO must run PV/AV at receipt, after encapsulation and at every stability time point — and use a nitrogen overlay during fill, antioxidant (mixed tocopherols, rosemary extract) in the fill, and oxygen-barrier blister or bottle packaging.
Line capability — rotary die, capsule shape, fill viscosity, throughput
Softgels are made on rotary-die encapsulation machines: two gelatin ribbons converge over the die, the fill is dosed at the wedge, the dies cut and seal the softgel in one stroke. The CMO's line capability is defined by die size range (typically 1–30 oblong, 3–30 round), shell composition (gelatin / HPMC / starch), fill viscosity range (5–10,000 cP), throughput per machine (typically 60,000–300,000 softgels/h), and the post-encapsulation tumble-dry and stage-dry environment (15–25°C, 20–30% RH over 12–48 h).
More on line capability — rotary die, capsule shape, fill viscosity, throughput
Ask: what dies will my SKU run on, what dose-CV at full speed, what is the validated stage-drying protocol, and what is the line's experience with the fill chemistry I propose.
21 CFR 111 + NSF 173 / USP <2750> overlay and the walk-away red flags
Subpart E component identity for the gelatin (CoA + identity test, plus CEP/COS for EU/UK lots). Subpart D cleaning validation per fill (oil-soluble actives are hard to remove; demand HBEL-derived MACO with TOC swab evidence).
More on 21 CFR 111 + NSF 173 / USP <2750> overlay and the walk-away red flags
Subpart K lab operations covering PV/AV/TOTOX, USP <2040> disintegration, USP <2023> microbial. NSF/ANSI 455-2 / USP <2750> add retailer-mandatory third-party testing. Walk-away red flags: (1) no fill-shell compatibility data on offer, (2) no cross-linking monitoring through stability, (3) bovine gelatin without CEP/COS chain, (4) no PV/AV/TOTOX programme for omega-3, (5) tumble-dry without environment qualification, (6) no HPMC/starch shell capability if you need vegan SKUs, (7) cleaning validation does not address fill carryover, (8) no NSF 173 / USP <2750> scope including softgels, (9) no documented overage for oxidisable actives, (10) line PPQ data not available on request.
Questions
Should I default to HPMC/starch shells instead of gelatin to avoid cross-linking?
Only if the marketing positioning requires vegan, you have a known cross-linking risk in the fill chemistry, or you are shipping to markets where animal-source documentation is a barrier. HPMC/starch shells cost more (20–40% premium), have a slightly narrower fill chemistry compatibility window, and the supply base is thinner. For most non-vegan SKUs gelatin with a controlled compatibility study and a low-aldehyde fill is the right answer.
How often should I retest fish-oil softgels for PV/AV/TOTOX?
At incoming oil receipt, after encapsulation (release), and at every stability time point (3, 6, 9, 12, 18, 24 months) at minimum. Trend the data — a stable supply chain and packaging should show TOTOX drifting up no more than 2–3 units across 24 months. A spike between time points is the early signal of nitrogen-overlay failure or packaging oxygen ingress.
Do I need a CEP/COS for bovine gelatin if I only sell in the US?
Legally, no — the US has its own BSE controls under 21 CFR 189.5 (and the gelatin supplier should hold a US-acceptable source statement). Practically, yes — major US retailers and most contract testing labs request the CEP/COS as the simplest defensible BSE/TSE evidence, and if you ever consider EU/UK distribution the gelatin chain must already be CEP/COS-traceable. Build the documentation discipline at launch.
What is the typical dose accuracy on a softgel line?
Validated fill weight CV is typically ±3% on a well-maintained rotary-die line with active wedge temperature control. The shell weight CV adds another ±2%. The combined finished-softgel CV under USP <2091> weight variation should fall comfortably within the supplement ±10% limit, but a tight-active SKU should request the per-die fill CV from the last PPQ batch before contracting.
Practical orientation, not legal advice. Rules differ by jurisdiction; your quality and compliance team decides what applies.
The Dietary Supplement Operations Guide
What the label says. What the batch proves.
- The rules and who decides
- Specification to finished batch
- Test, review, investigate
- Labels, samples and recall
Plus Evidence map and four worksheets.
Get the supplement guideWe ask for your name and email so we can handle this request. The full guide then opens on this site, ready to translate, print or save. Privacy policy. Practical orientation, not legal advice; your quality unit decides which rules apply.
UltimateFree guide
The Dietary Supplement Operations Guide
What the label says. What the batch proves.
Keep reading
- Gummy Supplement Contract Manufacturer Selection Guide
Gummy and Softgel Supplement Controls under 21 CFR 111
Supplement Contract Manufacturer Audit Checklist (21 CFR 111)
21 CFR 111 Readiness: Identity, Master and Batch Records
Africa Supplement Regulation: SAHPRA, NAFDAC & Kenya PPB
Supplement Allergen Control: Validated Cleaning and Labelling